Durvalumab Imfinzi®
Durvalumab is a human IgG1κ monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The SHIKARI® Durvalumab portfolio supports quantitative analysis of free durvalumab and qualitative detection of specific anti-durvalumab antibodies in human serum or plasma.
Why Durvalumab is relevant to biological-drug monitoring research
Durvalumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Durvalumab is a human IgG1κ monoclonal antibody directed against PD-L1, blocking its interactions with PD-1 and CD80 and reducing inhibitory immune signalling. Source ↗
Approved Indications
EMA-authorised uses cover defined settings across non-small cell and small cell lung cancers, biliary-tract cancer, hepatocellular carcinoma, endometrial cancer, muscle-invasive bladder cancer, and gastric or gastro-oesophageal junction adenocarcinoma. EMA source ↗
Dose-Selection Exposure Target
During original regimen development, a minimum serum exposure target was used to support dose selection:
Research-associated ranges, not universal treatment cut-offs. Values vary by endpoint, timing, assay method and population. This page is for RUO product information and does not provide clinical guidance.
Two verified Durvalumab research assays
Ligand-binding, sandwich-principle ELISA for quantitative analysis of free durvalumab capable of binding PD-L1 in human serum or plasma.
Sandwich-principle ELISA for qualitative screening of binding antibodies to durvalumab in human serum or plasma, reported as reactive or non-reactive according to the assay-specific interpretation criteria.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Mode | Analyte | Sample | Volume | Run Time | Analytical Output / LOD | Tests | Shelf Life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-DUR | DUR-FD-IMF | Quantitative | Free durvalumab | Human serum / plasma | 10 µL | 70 min | LOD 6 ng/mL · LOQ 10 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATDUR | DUR-QLS-IMF | Qualitative | Antibodies to durvalumab | Human serum / plasma | 20 µL | 140 min | Reactive / non-reactive | 96 | 1 year | 2–8°C | 10–30°C |
Q-DUR has a lowest detection limit (LOD) of 6 ng/mL and functional sensitivity (LOQ) of 10 ng/mL. Follow the link on each assay card for the current official product record on matriksbiotek.com.
Which assay fits your research question?
Choose the quantitative free-drug assay or qualitative anti-drug-antibody assay according to the analytical output required by the study.
Durvalumab Literature and Product-Use Records
Ready to order, or need technical guidance?
Matrix Biotek can help identify the appropriate Durvalumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.